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etter to the Editor
omatic  mutations  of  calreticulin  in a  Brazilian
ohort of  patients  with  myeloproliferative
eoplasms
ear Editor,
ssential thrombocythemia (ET), polycythemia vera (PV), and
rimary myeloﬁbrosis (PMF) are Philadelphia chromosome-
egative myeloproliferative neoplasms (MPNs) characterized
y increased myeloid proliferation. The gain of function
nduced by the Janus kinase 2 mutation, JAK2V617F, has been
eported in most PV and in more  than half of ET and PMF
ases.1 However, the presence of different disease phenotypes
nd the absence of the JAK2 mutation in some MPNs suggests
hat additional genetic lesions or/and aberrant signaling path-
ays may be involved in the pathogenesis of these diseases.1,2
In December 2013, somatic mutations in the calreticulin
CALR) gene were identiﬁed in ET and PMF patients by two
ndependent groups3,4 and conﬁrmed by others.5–9 CALR
utations have been reported as mutually exclusive with
AK2 and MPL mutations and may be present in 56–88% of
AK2/MPL-negative cases.3,4 A recent paper reported a patient
hat had both mutations, JAK2V617F and a CALR exon 9 muta-
ion, simultaneously.10 Over thirty different CALR mutations in
xon 9 have been described, but the most frequent mutations
about 80%) may be classiﬁed as type-1 [L367fs*46; deletion of
2 base pairs (bp)] and type-2 (K385fs*47; insertion of 5 bp).3,4
he functional changes induced by the mutations are still not
ompletely elucidated, but the overexpression of the type 1
ALR mutation in Ba/F3 cells (an IL3 dependent cell line) leads
o cytokine-independent cell growth and STAT5 activation.4
ene expression signature studies also indicate that JAK2 and
ALR mutations share mechanisms of malignant transfor-
ation, reafﬁrming a central role of the JAK/STAT signaling
athway in the pathogenesis of MPN.11
The aim of the present study was to characterize the
revalence of CALR mutations and the clinical and labora-
orial characteristics of CALR-mutated patients in a Brazilian
ohort of MPNs. Seventy-three MPN  patients were included in
he study (ET = 32, PV = 20, PMF  = 21). Patients’ characteristics
re described in Table 1. Peripheral blood samples were col-
ected, submitted to hemolysis, and DNA was extracted by thephenol/chloroform method. All samples were investigated for
JAK2 and CALR mutations. The JAK2V617F mutation and CALR
exon 9 mutations were veriﬁed as previously described.12,13
CALR mutations were classiﬁed as type-1 (deletion of 52 bp),
type-2 (insertion of 5 bp) or others (Figure 1).
In our cohort, CALR mutations were found in 20 patients
(13 ET and 7 PMF; Table 1) and were mutually exclusive with
JAK2V617F: 20/73 (27%) of total MPN  patients and 20/28 (71%)
of the JAK2WT patients. Among the CALR-mutated patients,
Type-1 CALR mutations were found in 50% (10/20; 8 ET and 2
PMF), type-2 in 40% (8/20; 4 ET and 4 PMF), and others in 10%
(1 ET and 1 PMF) of the individuals. CALR mutations were not
detected in PV patients (all JAK2V617F positive). In ET, CALRMUT
patients showed reduced hemoglobin levels compared with
JAK2V617F patients (p-value <0.01; Table 2); no differences were
observed in white blood cell, neutrophil and platelet counts,
thrombotic events, hepatomegaly, splenomegaly and consti-
tutional symptoms. In PMF  patients, CALR mutational status
was not associated with clinical features (Table 2). The fre-
quency of CALR mutations in this Brazilian cohort was similar
to previously described frequencies.3,4,7 Furthermore, CALR
and JAK2V617F mutations were mutually exclusive. Knowledge
regarding the clinical impact of CALR mutations in MPNs is
still under construction, but some studies indicate that CALR-
mutated patients have lower ages at disease onset, lower
hemoglobin and platelet counts, and have better overall sur-
vival than either JAK2-mutated or CALR/JAK2/MPL wild-type
patients.5,9,14 In our cohort, CALRMUT ET patients presented
lower hemoglobin levels, compared with JAK2V617F ET patients,
even though in both groups hemoglobin values remained
within the reference range.
In conclusion, CALR mutations are highly frequent in
Brazilian patients with MPN. The search for CALR mutations
may be a useful tool for MPN diagnosis and further research
on this mutation in Brazilian patients would be important to
deﬁne the local incidence of the mutation, to improve diagno-
sis and classiﬁcation of our patients, and to better evaluate the
impact of these mutations on the outcomes of MPN  patients.
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Table 1 – Patient characteristics.
MPN (n = 73) ET (n = 32) PV (n = 20) PMF (n = 21)
Age (years) – median (range): 57 (19–87) 53 (19–83) 70 (41–88) 62 (27–87)
Gender – male/female 30/43 10/22 9/11 11/10
Hemoglobin (g/dL) – median (range) 13.9 (8.1–22.7) 13.6 (9.7–17) 18.4 (12.8–22.7) 12.5 (8.1–19.9)
WBC count (×109 L–1) – median (range) 9.8 (2.4–43.2) 9 (3.0–17.8) 11.2 (6.3–25.5) 11.8 (2.4–43.2)
Platelet count (×109 L–1) – median (range) 764 (108–2065) 914 (541–2065) 609 (203–1070) 661 (108–1716)
JAK2 mutation status – n (%)
JAK2WT 28 (38) 20 (63) 0 (0) 8 (38)
JAK2V617F 45 (62) 12 (37) 20 (100) 13 (62)
CALR mutation status – n (%)
CALRWT 53 (73) 19 (59) 20 (100) 14 (67)
CALRMUT 20 (27) 13 (41) 0 (0) 7 (33)
MPN: myeloproliferative neoplasms; ET: essential thrombocythemia; PV: polycythemia vera; PMF: primary myeloﬁbrosis; WBC: white blood cell
count; JAK2:  Janus kinase 2 gene; WT: wild-type; CALR: Calreticulin gene; MUT: exon 9 mutations.
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Figure 1 – Calreticulin (CALR) indel mutations in myeloproliferative neoplasm (MPN) patients. (A) PCR ampliﬁcation of exon 9
of CALR gene loaded on 4% agarose gel; lane 1: 100 bp marker (M); lane 2: no template control (NTC); MPN  patients #1 and #2:
CALRWT; #3 and #4: heterozygotes for type-1 CALR mutation (CALRWT amplicons: 297 bp; type-1 CALRMUT amplicons: 245 bp);
#5 and #6: heterozygotes for type-2 CALR mutation (CALRWT amplicons: 297; type-2 CALRMUT amplicons: 302 bp); #7:
heterozygote for non-type-1 or -2 CALR mutation (CALRWT amplicons: 297 bp; CALRMUT amplicons: 291 bp). (B)
Representative PCR fragment size analysis of CALR amplicons from MPN  patients: the orange peaks represent the GeneScan
500 LIZ dye Size Standard and blue peaks represent the CALR amplicons; the black arrows indicate the wild-type allele
(297 bp) and the red arrows indicate the indel-mutation alleles.
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